Е. П. Иливанова

648 total citations
21 papers, 448 citations indexed

About

Е. П. Иливанова is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Е. П. Иливанова has authored 21 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 10 papers in Immunology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Е. П. Иливанова's work include Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Lupus Erythematosus Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Е. П. Иливанова is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Systemic Lupus Erythematosus Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Е. П. Иливанова collaborates with scholars based in Russia, Belarus and Austria. Е. П. Иливанова's co-authors include Josef S Smolen, Patrick Durez, Stephen Hall, Peter Nash, Min‐Chan Park, Pedro C. Miranda, Karel Pavelká, Andrew Koenig, Annette Szumski and Constance Hammond and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Annals of the Rheumatic Diseases.

In The Last Decade

Е. П. Иливанова

19 papers receiving 435 citations

Peers

Countries citing papers authored by Е. П. Иливанова

Since Specialization

Citations

This map shows the geographic impact of Е. П. Иливанова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Е. П. Иливанова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Е. П. Иливанова more than expected).

Fields of papers citing papers by Е. П. Иливанова

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Е. П. Иливанова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Е. П. Иливанова. The network helps show where Е. П. Иливанова may publish in the future.

Co-authorship network of co-authors of Е. П. Иливанова

This figure shows the co-authorship network connecting the top 25 collaborators of Е. П. Иливанова. A scholar is included among the top collaborators of Е. П. Иливанова based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Е. П. Иливанова. Е. П. Иливанова is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy 2024 ·SHILAP Revista de lepidopterología ·P. А. Shesternya, А. А. Баранов, (unknown), (unknown), (unknown), Е. А. Богданова, (unknown), Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), O. B. Nesmeyanova, (unknown), (unknown), (unknown), Е. Л. Насонов, А. М. Лила	0
2	Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab) 2023 ·SHILAP Revista de lepidopterología ·А. А. Баранов, (unknown), (unknown), (unknown), Е. А. Богданова, (unknown), Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), O. B. Nesmeyanova, (unknown), P. А. Shesternya, (unknown), Eugen Feist, Е. Л. Насонов	2
3	Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study 2021 ·SHILAP Revista de lepidopterología ·Mazurov Vi, (unknown), I. Z. Gaydukova, Е. П. Иливанова, (unknown), (unknown), O. B. Nesmeyanova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	9
4	FRI0114 EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY 2020 ·Annals of the Rheumatic Diseases ·Mazurov Vi, (unknown), Е. П. Иливанова, (unknown), (unknown), O. B. Nesmeyanova, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
5	A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 2: Evaluation of the efficacy of the drug in different use regimens 2020 ·SHILAP Revista de lepidopterología ·(unknown), Л. И. Алексеева, Е. А. Таскина, (unknown), (unknown), (unknown), А. М. Лила, (unknown), Н. А. Шостак, Е. Шмидт, Е. П. Иливанова	6
6	A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study 2019 ·Rheumatology International ·(unknown), Mazurov Vi, (unknown), O. B. Nesmeyanova, Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), Roman Ivanov	8
7	FRI0412 SPINAL AND SACROILIAC JOINTS INFLAMMATION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS TREATED WITH NETAKIMAB – 16-WEEKS RESULTS OF MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III ASTERA STUDY 2019 ·Annals of the Rheumatic Diseases ·(unknown), I. Z. Gaydukova, Mazurov Vi, Ш. Ф. Эрдес, (unknown), O. B. Nesmeyanova, Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), Roman Ivanov	3
8	FRI0391 NETAKIMAB IMPROVES PATIENT-RELATED OUTCOMES IN PATIENTS WITH RADIOLOGICAL AXIAL SPONDYLOARTHRITIS: RESULTS FROM RANDOMISED PHASE 3 TRIAL (ASTERA) 2019 ·Annals of the Rheumatic Diseases ·I. Z. Gaydukova, Mazurov Vi, Ш. Ф. Эрдес, (unknown), O. B. Nesmeyanova, Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), (unknown), Roman Ivanov	2
9	FRI0108 SHORT-TERM EFFICACY OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 12-WEEK RESULTS OF PHASE 2 AURORA STUDY 2019 ·Annals of the Rheumatic Diseases ·Mazurov Vi, (unknown), Е. П. Иливанова, (unknown), (unknown), O. B. Nesmeyanova, (unknown), (unknown), (unknown), (unknown), (unknown), Roman Ivanov	3
10	A multicenter, prospective, randomized trial of the efficacy and safety of Alflutop® in an alternating dosing regimen versus the standard one. Communication 1: Evaluation of the efficacy of the drug in different treatment regimens 2019 ·SHILAP Revista de lepidopterología ·(unknown), Е. А. Таскина, А. М. Лила, Mazurov Vi, Н. А. Шостак, Е. Шмидт, Е. П. Иливанова	15
11	THU0193 Efficacy and safety of bcd-055 (INFLIXIMAB BIOSIMILAR) in rheumatoid arthritis. results of bcd-055–3/lira phase 3 clinical study 2018 ·Annals of the Rheumatic Diseases ·А. М. Лила, (unknown), (unknown), С. А. Смакотина, (unknown), (unknown), A. A. Кastanayan, O. B. Nesmeyanova, (unknown), Е. П. Иливанова, (unknown), (unknown), (unknown), Roman Ivanov	2
12	A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate 2017 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Sandeep K. Agarwal, Е. П. Иливанова, Xie L. Xu, Miao Ye, Yanli Zhuang, Ivo Nnane, Waldemar Radziszewski, Andrew Greenspan, Anna Beutler, Daniel L. Baker	113
13	FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximab 2017 ·Annals of the Rheumatic Diseases ·(unknown), И. Г. Гордеев, Mazurov Vi, А. М. Лила, Е. В. Зонова, O. B. Nesmeyanova, Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), Roman Ivanov, (unknown), (unknown), (unknown)	1
14	ОСОБЕННОСТИ ПОРАЖЕНИЯ МИКРОЦИРКУЛЯТОРНОГО РУСЛА ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ 2016 ·(unknown), (unknown), (unknown), Е. П. Иливанова, А. О. Конради, (unknown)	1
15	OP0031 A Phase 2 Study Evaluating the Efficacy and Safety of Subcutaneously Administered Ustekinumab and Guselkumab in Patients with Active Rheumatoid Arthritis Despite Treatment with Methotrexate 2015 ·Annals of the Rheumatic Diseases ·J S Smolen, (unknown), Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), (unknown), Andrew Greenspan, Anna Beutler, Daniel Baker	4
16	ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES 2014 ·Medical Immunology (Russia) ·(unknown), (unknown), (unknown), Е. П. Иливанова, Арег А. Тотолян	4
17	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial 2013 ·The Lancet ·Josef S Smolen, Peter Nash, Patrick Durez, Stephen Hall, Е. П. Иливанова, Fedra Irazoque-Palazuelos, Pedro C. Miranda, Min‐Chan Park, Karel Pavelká, Ronald Pedersen, Annette Szumski, Constance Hammond, Andrew Koenig, Bonnie Vlahos	267
18	Combination pulse therapy with methotrexate and dexamethasone in patients with early rheumatoid arthritis and poor prognostic factors: an open-label randomized trial 2013 ·SHILAP Revista de lepidopterología ·(unknown), Е. П. Иливанова, (unknown), (unknown), (unknown), С. В. Лапин, (unknown), Mazurov Vi	1
19	DIAGNOSTIC VALUE OF SEROLOGICAL MARKERS OF RHEUMATOID ARTHRITIS 2012 ·SHILAP Revista de lepidopterología ·(unknown), С. В. Лапин, (unknown), (unknown), (unknown), (unknown), (unknown), Е. П. Иливанова, (unknown), Mazurov Vi	2
20	New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol 2012 ·SHILAP Revista de lepidopterología ·Д. Е. Каратеев, (unknown), (unknown), Marina Stanislav, (unknown), (unknown), Mazurov Vi, (unknown), Yu. P. Uspensky, (unknown), Е. П. Иливанова, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact